



## **Synta Pharmaceuticals to Host Second-Quarter 2008 Conference Call on August 7, 2008**

July 29, 2008

LEXINGTON, Mass.--(BUSINESS WIRE)--July 29, 2008--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it will release its second-quarter 2008 financial results before the market opens on Thursday, August 7, 2008.

Management will conduct a conference call at 10:00 a.m. (ET) that morning to review the Company's second-quarter financial results. The conference call will be webcast live over the Internet and can be accessed by logging on to the "Investors" section of the Synta Pharmaceuticals website, [www.syntapharma.com](http://www.syntapharma.com), prior to the event.

The call also can be accessed by dialing (877) 407-8035 or (201) 689-8035 prior to the start of the call. For those unable to join the live conference call, a replay will be available from 2:00 p.m. (ET) on August 7 through midnight (ET) on August 17. To access the replay, dial (877) 660-6853 or (201) 612-7415 and refer to both account number 286 and conference ID 291487. The webcast also will be archived on the Company's website.

### **About Synta Pharmaceuticals**

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit [www.syntapharma.com](http://www.syntapharma.com).

CONTACT: Synta Pharmaceuticals Corp.  
Rob Kloppenburg, 781-541-7125  
or  
MacDougall Biomedical Communications  
Doug MacDougall, 781-235-3060

SOURCE: Synta Pharmaceuticals Corp.